The market anticipates continued poor revenue growth, potent...
The market anticipates continued poor revenue growth, potentially suppressing the P/S ratio. The company's forecast of declining revenue contributes to its low P/S. Without major changes, a drastic stock price increase seems unlikely.
There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 50% Share Price Rise
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment